Cancer Biomarkers - Volume 24, issue 2

Authors: Pasha, Heba F. | Mohamed, Randa H. | Radwan, Mohamed I.

Article Type: Research Article

Abstract: BACKGROUND: DNA methylation status is one of the most prevalent molecular alterations in human cancers. Identification of powerful diagnostic and prognostic biomarkers for hepatocellular carcinoma (HCC) without a biopsy is urgently required. OBJECTIVE: The purpose of this study was to determine the methylation status of RASSF1A and SOCS-1genes as a non-invasive biomarker for HCC identification and prognosis. METHODS: Methylation specific-PCR technique was performed to recognize the methylation status of RASSF1A and SOCS-1 genes in 100 patients with HCC, 100 patients with liver cirrhosis (LC) but without HCC were considered as cirrhotic liver control …group and 100 healthy control. RESULTS: Methylation of RASSF1A and SOCS-1 genes were detected in 40% and 38% of HCC patients respectively, 14% and 20% of LC patients respectively. Methylation of SOCS-1 gene in peripheral blood of healthy control was 23%. Methylation of RASSF1A gene was associated with age, tumor size, vascular invasion and α fetoprotein (AFP), while SOCS-1 gene methylation was significantly associated with tumor size and AFP. Furthermore, using RASSF1A/ SOCS-1/ AFP panel improve diagnostic sensitivity for HCC 86% and specificity of 75%. CONCLUSION: RASSF1A and SOCS1 genes methylation status may play an important role in the process of hepatocarcinogenesis and may be used as diagnostic and prognostic noninvasive biomarkers for HCC when combined with serum AFP. Show more

Keywords: Hepatocellular carcinoma, methylation, SOCS-1, RASSF1A

DOI: 10.3233/CBM-181638

Citation: Cancer Biomarkers, vol. 24, no. 2, pp. 241-247, 2019

Authors: Ji, Bing | Huang, Youmin | Gu, Ting | Zhang, Li’e | Li, Guohong | Zhang, Changgeng

Article Type: Research Article

Abstract: BACKGROUND: Plasma carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4) are common markers which are useful in the diagnosis and prognosis of GC. However, their sensitivity and specificity in GC remain unsatisfactory. Identification of cancer diagnosed-biomarkers would be of great value. OBJECTIVE: Evaluate the diagnostic and prognostic value of LINC00086 and miR-214 in GC. METHODS: In this study, we determined the expression of LINC00086 and miR-214 in GC by qRT-PCR. Additionally, we investigated the relationship between various clinicopathological features of GC patients and LINC00086 or miR-214 expression, and evaluated the diagnostic …and prognostic value of LINC00086 and miR-214 in GC. RESULTS: In this study, we found that plasma LINC00086 expression was significantly lower, whereas plasma miR-214 expression was significantly higher in GC patients than in normal individuals. LINC00086 and miR-214 exhibited high sensitivity and specificity in diagnosing GC. Additionally, GC patients with low LINC00086 or high miR-214 expression were likely to have larger tumors, lymphatic metastasis, larger TNM stage, and higher CEA and CA19-9 levels. Moreover, GC patients with low LINC00086 or high miR-214 expression showed lower survival rates. Lymphatic metastasis, LINC00086, and miR-214 are independent factors affecting patient diagnosis. CONCLUSIONS: LINC00086 and miR-214 are potentially diagnostic and prognostic markers for GC. Show more

Keywords: Gastric cancer, LINC00086, miR-214, diagnosis, prognosis

DOI: 10.3233/CBM-181486

Citation: Cancer Biomarkers, vol. 24, no. 2, pp. 249-255, 2019